Women's Health & Pregnancy Clinical Trials

Statistical methods in women's health & pregnancy trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All women's health & pregnancy trials

790 results

• Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00285857).Phase 2Results postedn = 30NCT00285857
• Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant: Complete Statistical AnalysisIndependent statistical analysis of Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 51NCT04224272
• Phase I Combination w/ Epirubicin: Complete Statistical AnalysisIndependent statistical analysis of Phase I Combination w/ Epirubicin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00322374).Phase 1Results postedn = 42NCT00322374
• Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 1/2Results postedn = 252NCT02608268
• Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1/2Results postedn = 61NCT02348008
• Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 5NCT00630409
• Phase II Dasatinib Study in Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Dasatinib Study in Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00546104).Phase 2Results postedn = 31NCT00546104
• Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC: Complete Statistical AnalysisIndependent statistical analysis of Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 60NCT00709761
• Phase II Neoadjuvant in Inflammatory Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Neoadjuvant in Inflammatory Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00756470).Phase 2Results postedn = 15NCT00756470
• Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00379197).Phase 2Results postedn = 13NCT00379197
• Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer: primary endpoint results, effect estimate…Phase 2Results postedn = 141NCT01008150
• Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 33NCT01928680
• Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 70NCT00912340
• Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 30NCT00542191
• Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 21NCT02401347
• Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 304NCT01037790
• Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 375NCT00770874
• PHE-LEEPIndependent statistical analysis of Cryotherapy vs. LEEP to Treat Cervical Intraepithelial Neoplasia (CIN) 2/3 Among HIV-positive Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 400NCT01298596
• Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced – Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay: Complete Statistical AnalysisIndependent statistical analysis of Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced - Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 7NCT05811377
• PHranceSCaIndependent statistical analysis of A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer: primary endpoint…Phase 2Results postedn = 160NCT03674112
• Physical Therapy Intervention for Puerperal Mastitis: Complete Statistical AnalysisIndependent statistical analysis of Physical Therapy Intervention for Puerperal Mastitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04569136).Phase NAResults postedn = 37NCT04569136
• PICLSIndependent statistical analysis of Pregnancy Intervention With a Closed-Loop System (PICLS) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03774186).Phase NAResults postedn = 24NCT03774186
• Pilot Assessment of an Auto Blood Pressure Monitor: Complete Statistical AnalysisIndependent statistical analysis of Pilot Assessment of an Auto Blood Pressure Monitor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02258256).Phase NAResults postedn = 11NCT02258256
• Pilot Clinical Study on a Low-power Electromagnetic Wave Breast Imaging Device for Cancer Screening Purposes.: Complete Statistical AnalysisIndependent statistical analysis of Pilot Clinical Study on a Low-power Electromagnetic Wave Breast Imaging Device for Cancer Screening Purposes.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 25NCT03475992
• Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 20NCT02282930
• Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC): Complete Statistical AnalysisIndependent statistical analysis of Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC): primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 1Results postedn = 33NCT02001974
• Pilot Study to Evaluate Safety, Tolerability, and Performance of the FAST PV Technology™ in Chronic Dialysis Patients: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study to Evaluate Safety, Tolerability, and Performance of the FAST PV Technology™ in Chronic Dialysis Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 10NCT04733664
• Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 122NCT02872103
• PLANET 1Independent statistical analysis of Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 353NCT00296374
• PLUMIndependent statistical analysis of Post-Prandial Liver Glucose Metabolism in PCOS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03041129).Phase NAResults postedn = 19NCT03041129
• PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer: Complete Statistical AnalysisIndependent statistical analysis of PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 1/2Results postedn = 37NCT04493619
• pNAATIndependent statistical analysis of Performance of Nucleic Acid Amplification Tests for the Detection of NG and CT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 2,767NCT02870101
• PNS_UDTIndependent statistical analysis of Acute Pudendal Nerve Stimulation On Leak Point Pressure In Women Urodynamic Early Feasibility Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 4NCT05128682
• POCHARBIIndependent statistical analysis of Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase NAResults postedn = 290NCT01298362
• PODOIndependent statistical analysis of A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 47NCT03448692
• PolenIndependent statistical analysis of Preoperative Olaparib Endometrial Carcinoma Study (POLEN): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02506816).Phase NAResults postedn = 36NCT02506816
• POLLYIndependent statistical analysis of ER Reactivation Therapy for Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02188745).Phase 2Results postedn = 20NCT02188745
• Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 19NCT02810873
• POSTOPIndependent statistical analysis of Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01377467).Phase 3Results postedn = 90NCT01377467
• Postpartum Pelvic Floor Muscle Training in Women With and Without Injured Pelvic Floor Muscles: Complete Statistical AnalysisIndependent statistical analysis of Postpartum Pelvic Floor Muscle Training in Women With and Without Injured Pelvic Floor Muscles: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 175NCT01069484
• Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries: Complete Statistical AnalysisIndependent statistical analysis of Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03470675).Phase 4Results postedn = 67NCT03470675
• POWERIndependent statistical analysis of Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 84NCT04272801
• POWER PIINCIndependent statistical analysis of Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01614210).Phase 2Results postedn = 52NCT01614210
• PPRIndependent statistical analysis of RCT: Can a Single Counseling Phone Call Improve Contraception After an Abortion?: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 207NCT01199952
• Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody: Complete Statistical AnalysisIndependent statistical analysis of Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 226NCT00606632
• PrE0801Independent statistical analysis of NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 3NCT01649180
• PRECAUTIONIndependent statistical analysis of Prevention of Catheter-Associated Urinary Tract Infection in Incontinence and Reconstructive Pelvic Surgery Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 52NCT01108757
• Prediction of Postsurgical Symptomatic Outcomes With Preoperative Pessary Use: Complete Statistical AnalysisIndependent statistical analysis of Prediction of Postsurgical Symptomatic Outcomes With Preoperative Pessary Use: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02680145).Phase NAResults postedn = 58NCT02680145
• PreFaiRIndependent statistical analysis of Comparative Effectiveness of Pregnancy Failure Management Regimens: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02012491).Phase 3Results postedn = 300NCT02012491
• PrefHERIndependent statistical analysis of Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 488NCT01401166

← All therapeutic areas